Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, multicentre, randomized, open- label, 3-parallel groups, phase 2 study to evaluate efficacy and safety of masitinib at 9 mg/kg/day in combination with oxaliplatin, 5‐fluorouracil (5-FU) and folinic acid (FOLFOX) or in combination with irinotecan, 5-fluorouracil (5-FU) and folinic acid (FOLFIRI) or in combination with gemcitabine (GEM) in the treatment of patients with metastatic colorectal cancer in progression after a first line treatment.

Trial Profile

A prospective, multicentre, randomized, open- label, 3-parallel groups, phase 2 study to evaluate efficacy and safety of masitinib at 9 mg/kg/day in combination with oxaliplatin, 5‐fluorouracil (5-FU) and folinic acid (FOLFOX) or in combination with irinotecan, 5-fluorouracil (5-FU) and folinic acid (FOLFIRI) or in combination with gemcitabine (GEM) in the treatment of patients with metastatic colorectal cancer in progression after a first line treatment.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Masitinib (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2015 Status changed from recruiting to completed, according to an AB Science media release.
    • 02 Jun 2015 Safety results in masitinib + FOLFIRI treatment group presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 18 May 2015 According to an AB Science media release, data from this study will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top